To investigate the prevalence of p53 mutations and associated factors between immunohistochemistry (IHC) and p53 staining patterns among patients with high-grade serous ovarian carcinoma (HGSOC). MethodsThis study is a retrospective review. A total of 62 patients with HGSOC underwent surgery at Srinagarind Hospital between January 2016 and December 2020. Histological examination was performed based on a combination of morphology and IHC staining with p53. The p53 immunostaining pattern was interpreted as a missense mutation, nonsense mutation, or a wild-type pattern. Missense (p53 overexpression pattern) and nonsense (null expression p53 pattern) mutations were considered p53 mutations. A wild-type pattern was defined as a p53 non-mutation. Resultsp53 mutations were identified in 93.6% of the patients. Subgroup analysis of the p53 mutation group between the p53 overexpression pattern and the p53 null expression pattern in terms of clinicopathological characteristics and initial treatment was performed. Patients with the p53 overexpression pattern had significantly more omental metastases than those with the p53 null expression pattern (87.8% vs. 64.7%, P=0.042). There were no statistically significant differences in median progression-free survival (PFS) (9 vs. 10 months, P=0.813) or median overall survival (OS) (12 vs. 17 months, P=0.526) between the two groups. ConclusionThe prevalence of p53 mutations in HGSOC patients in this study was 93.6%. Omental metastasis is a significant pathological factor in predicting overexpression p53 pattern in HGSC. However, IHC analysis of the p53 staining pattern did not affect OS or PFS among patients with HGSOC.
Objective: To investigate the prevalence of p53 mutations and the associated factors between the immunohistochemistry (IHC) of p53 staining pattern among patients with high-grade serous ovarian carcinoma (HGSOC). Methods:The study was a retrospective study and enrolled a total of 62 patients with HGSOC, who underwent surgery in Srinagarind Hospital, between January 2016 and December 2020. Histological examination was reveal based on the combination of morphology and IHC staining with p53. The p53 immunostaining pattern was interpreted as a missense mutation, nonsense mutation, or wild-type pattern. Missense (p53 overexpression pattern) and nonsense mutation (null expression p53 pattern) were considered to be p53 mutation. A wide-type pattern was defined as p53 non-mutation. Results: The p53 mutation was identified in 93.55% of patients. When subgroup analysis in p53 mutation group between overexpression p53 pattern and null expression p53 pattern in terms of clinicopathological characteristic and initial treatment was performed. Patients with overexpression p53 pattern had more omental metastasis compared to those with null expression p53 pattern (90.0% vs. 64.7%, p=0.042). There were no statistically significant differences in terms of progression free survival (PFS) (9 months vs. 10 months, p=0.813) and overall survival (OS) (12 months vs. 17 months, p=0.526) were observed between the 2 groups. Conclusion:The prevalence of p53 mutations in HGSOC in this study was 93%. Omental metastasis is the one significant pathological factor for predicting an overexpression p53 pattern of HGSOC. However, IHC of p53 staining pattern did not impact on OS and PFS among patients with HGSOC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.